Your shopping cart is currently empty

KAG-308 is an effective selective and orally active agonist of the EP4 receptor (Ki: 2.57 nM and EC50: 17 nM for human EP4 receptor), more selective over EP1, EP2, EP3, and IP receptor. KAG-308 suppresses colitis and promotes histological mucosal healing, which potently inhibits TNF-α production.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $13,500 | 3-6 months | 3-6 months | |
| 50 mg | $19,000 | 3-6 months | 3-6 months | |
| 100 mg | $26,700 | 3-6 months | 3-6 months |
| Description | KAG-308 is an effective selective and orally active agonist of the EP4 receptor (Ki: 2.57 nM and EC50: 17 nM for human EP4 receptor), more selective over EP1, EP2, EP3, and IP receptor. KAG-308 suppresses colitis and promotes histological mucosal healing, which potently inhibits TNF-α production. |
| Targets&IC50 | IP receptor (human):52.9 nM(ki), EP2 receptor (human):1540 nM(ki), EP3 receptor (human):32.4 nM(ki), EP1 receptor (human):1410 nM(ki), EP4 receptor (human):(ki)2.57 nM, EP2 receptor (human):1000 nM(EC50), EP3 receptor (human):160 nM(EC50), EP4 receptor (human):(EC50)17 nM |
| In vitro | KAG-308 shows effective agonist activity for human and mouse EP4 (EC50: 0.15 nM and 1.0 nM, respectively in the dual luciferase reporter assay). KAG-308 shows a Ki and EC50 values of 2.57 nM and 17 nM for human EP4 receptor, respectively, more selective over human EP1 (Ki, 1410 nM; EC50, 1000 nM), EP2 (Ki, 1540 nM; EC50, 1000 nM), EP3 (Ki, 32.4 nM; EC50, 160 nM) and IP receptor (Ki, 52.9 nM; EC50, >10000 nM) [1]. |
| Molecular Weight | 460.52 |
| Formula | C24H30F2N4O3 |
| Cas No. | 1215192-68-9 |
| Smiles | [H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)[C@H](C)c3cccc(C)c3)[C@@]1([H])C(F)(F)\C(O2)=C\CCCc1nnn[nH]1 |
| Relative Density. | 1.32 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.